Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

van der Poel Henk

首页> 外文期刊>European urology >Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

【24h】

Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

机译：Re：向抗阉割前列腺癌和骨转移患者中添加镭酮和泼尼松或泼尼松龙（ERA 223）：随机，双盲，安慰剂，第3期试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European urology》 |2019年第5期|共3页
作者
van der Poel Henk;
展开▼
作者单位

Netherlands Canc Inst Dept Urol Plesmanlaan 121 NL-1066 CX Amsterdam Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . Smith Matthew, Parker Chris, Saad Fred, The lancet oncology . 2019,第3期

机译：在抗阉割的前列腺癌和骨转移患者中添加镭-223至Abiraatorone醋酸盐和泼尼松或泼尼松龙（ERA 223）：A随机，双盲，安慰剂控制，第3期试验
2. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 408, 2019) [J] . Smith M., Parker C., Saad F. The lancet oncology . 2019,第10期

机译：在抗阉割前列腺癌和骨转移患者中添加镭的醋酸盐和泼尼松或泼尼松酮（ERA 223）：随机，双盲，安慰剂控制，第3期试验（Vol 20，PG 408,2019 的）
3. Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial [J] . van der Poel Henk European urology . 2019,第5期

机译：Re：向抗阉割前列腺癌和骨转移患者中添加镭酮和泼尼松或泼尼松龙（ERA 223）：随机，双盲，安慰剂，第3期试验
4. Radium-223 Dichloride Monotherapy and Combination Therapy with Zoledronic Acid or Doxorubicin Improve Survival in a Mouse Model of Breast Cancer Bone Metastasis [C] . Jukka Rissanen, Mari Suominen, Rami K?k?nen, Molecular Medicine TRI-CON. . 2014

机译：镭-223二氯化物单疗法和组合治疗唑醇或多柔比星改善了乳腺癌骨转移的小鼠模型中的存活
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide [O] . D.P. Petrylak, U.N. Vaishampayan, K.R. Patel, 2021

机译：含镭-223二氯化钠或与AbiraTerone醋酸盐/泼尼松或苯甲酸丁酰胺组合处理的转移阉割抗性前列腺癌（MCRPC）的量化骨扫描响应的随机相IIA研究
7. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide [O] . D.P. Petrylak, U.N. Vaishampayan, K.R. Patel, 2021

机译：含镭-223二氯化钠或与AbiraTerone醋酸盐/泼尼松或苯甲酸丁酰胺组合处理的转移阉割抗性前列腺癌（MCRPC）的量化骨扫描响应的随机相IIA研究

Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

著录项

相似文献

相关主题

期刊订阅